Eloxx Pharmaceuticals, Inc. Common Stock
ELOX
ELOX was delisted on the 13th of October, 2023.
46 hedge funds and large institutions have $29.4M invested in Eloxx Pharmaceuticals, Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 10 increasing their positions, 10 reducing their positions, and 13 closing their positions.
69% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 13
24% more funds holding
Funds holding: 37 → 46 (+9)
3% more capital invested
Capital invested by funds: $28.6M → $29.4M (+$790K)
0% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 10
5% less call options, than puts
Call options by funds: $604K | Put options by funds: $636K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$4.73M |
| 2 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
+$3.94M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.89M |
| 4 |
AFG
American Financial Group
Cincinnati,
Ohio
|
+$3.09M |
| 5 |
ACM
Altium Capital Management
New York
|
+$1.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$2.79M |
| 2 |
State Street
Boston,
Massachusetts
|
-$518K |
| 3 |
N
Nuveen
Charlotte,
North Carolina
|
-$377K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$324K |
| 5 |
JP Morgan Chase
New York
|
-$148K |
ELOX Hedge Fund Activity: Q2 2021 in Review
46 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Eloxx Pharmaceuticals, Inc. Common Stock (ELOX) for Q2 2021, worth a combined $29.4M — up 2.8% from $28.6M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new ELOX positions and 13 closed out — a net gain of 9 holders — while 10 added to existing stakes and 10 trimmed.
The largest buyer was Nantahala Capital Management, opening a new position worth an estimated $4.73M. The largest seller was BlackRock, cutting an estimated $2.79M.
- 46 institutional investors held Eloxx Pharmaceuticals, Inc. Common Stock (ELOX) as of Q2 2021, up from 37 in Q1 2021.
- Funds reported $29.4M of Eloxx Pharmaceuticals, Inc. Common Stock stock for Q2 2021, up 2.8% quarter-over-quarter.
- 22 funds opened new Eloxx Pharmaceuticals, Inc. Common Stock positions in Q2 2021 and 13 closed out, a net change of +9 holders.
- The largest Eloxx Pharmaceuticals, Inc. Common Stock buyer in Q2 2021 was Nantahala Capital Management, an estimated $4.73M added.
- The largest Eloxx Pharmaceuticals, Inc. Common Stock seller in Q2 2021 was BlackRock, an estimated $2.79M sold.
Based on aggregated 13F filings for Q2 2021.